Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma.
Twenty-seven children with abdominal Burkitt's lymphoma (stage III), who had achieved complete remission, were entered into a prospective controlled trial of adjunct treatment with Epstein-Barr virus (EBV)-specific transfer factor (TF). Two patients treated with TF and 2 controls relapsed early (less than or equal to 12 weeks). Two out of 12 TF-treated patients and 5 out of 11 controls subsequently suffered relapses. Time to first late relapse was longer among TF-treated patients (p = 0.08), and no late relapse occurred while a patient was receiving TF treatment. Thus it seems that specific TF might be useful in the management of endemic Burkitt's lymphoma and also in the treatment of other virus-associated cancers and diseases.
Neequaye
J
J
University of Ghana School of Medicine, Accra.
Viza
D
D
Pizza
G
G
Levine
P H
PH
De Vinci
C
C
Ablashi
D V
DV
Biggar
R J
RJ
Nkrumah
F K
FK
D000008:Abdominal Neoplasms / Q000628:therapy*; D000293:Adolescent; D002051:Burkitt Lymphoma / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D004854:Herpesvirus 4, Human / Q000187:drug effects*; D006801:Humans; D008297:Male; D012008:Recurrence; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor